Compile Data Set for Download or QSAR
Report error Found 24 Enz. Inhib. hit(s) with all data for entry = 10820
TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571393(4-chloro-N-(4-(((3aR,6aS)-tetrahydro-1H-furo[3,4-c...)
Affinity DataIC50: 200nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571394(4-chloro-N-(4-((4-hydroxypiperidin-1-yl)methyl)phe...)
Affinity DataIC50: 200nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571386(N-(4-((1,4-oxazepan-4-yl)methyl)phenyl)-4-chlorobe...)
Affinity DataIC50: 600nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571390(N-(4-((7-oxa-2-azaspiro[3.5]nonan-2-yl)methyl)phen...)
Affinity DataIC50: 700nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571386(N-(4-((1,4-oxazepan-4-yl)methyl)phenyl)-4-chlorobe...)
Affinity DataIC50: 700nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571396(4-chloro-N-(4-((4-methylpiperazin-1-yl)methyl)phen...)
Affinity DataIC50: 700nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571387(N-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phe...)
Affinity DataIC50: 1.00E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571389(2-chloro-N-(4-(morpholinomethyl)phenyl)pyrimidine-...)
Affinity DataIC50: 1.20E+3nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571387(N-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phe...)
Affinity DataIC50: 1.20E+3nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571393(4-chloro-N-(4-(((3aR,6aS)-tetrahydro-1H-furo[3,4-c...)
Affinity DataIC50: 1.30E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571390(N-(4-((7-oxa-2-azaspiro[3.5]nonan-2-yl)methyl)phen...)
Affinity DataIC50: 1.40E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571394(4-chloro-N-(4-((4-hydroxypiperidin-1-yl)methyl)phe...)
Affinity DataIC50: 1.60E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571386(N-(4-((1,4-oxazepan-4-yl)methyl)phenyl)-4-chlorobe...)
Affinity DataIC50: 1.80E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571390(N-(4-((7-oxa-2-azaspiro[3.5]nonan-2-yl)methyl)phen...)
Affinity DataIC50: 2.10E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571394(4-chloro-N-(4-((4-hydroxypiperidin-1-yl)methyl)phe...)
Affinity DataIC50: 2.10E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571396(4-chloro-N-(4-((4-methylpiperazin-1-yl)methyl)phen...)
Affinity DataIC50: 2.70E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571393(4-chloro-N-(4-(((3aR,6aS)-tetrahydro-1H-furo[3,4-c...)
Affinity DataIC50: 2.80E+3nMAssay Description:The SARS-CoV-2 isolate BetaCoV/France/IDF0372/2020 (SARS-CoV-2 Paris) was supplied by the National Reference Centre for Respiratory Viruses hosted by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571391(N-(4-((1-oxa-7-azaspiro[4.4]nonan-7-yl)methyl)phen...)
Affinity DataIC50: 2.90E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571392(N-(4-(((1R,5S)-3-oxa-7-azabicyclo[3.3.1]nonan-7-yl...)
Affinity DataIC50: 3.10E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571395(4-chloro-N-(4-((3-hydroxypyrrolidin-1-yl)methyl)ph...)
Affinity DataIC50: 3.40E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571396(4-chloro-N-(4-((4-methylpiperazin-1-yl)methyl)phen...)
Affinity DataIC50: 3.60E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571391(N-(4-((1-oxa-7-azaspiro[4.4]nonan-7-yl)methyl)phen...)
Affinity DataIC50: 6.40E+3nMAssay Description:After infection, supernatants were removed, and cells were fixed with 4% formaldehyde for 24 hours prior to being removed from the BSL-3 facility. Th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571387(N-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phe...)
Affinity DataIC50: 7.80E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetSpike glycoprotein(2019-nCoV)
Gen1E Lifesciences

US Patent
LigandPNGBDBM571389(2-chloro-N-(4-(morpholinomethyl)phenyl)pyrimidine-...)
Affinity DataIC50: 9.40E+3nMAssay Description:Cells were seeded in 24-well plates at a concentration of 7.5×104 cells/well. The following day, serial dilutions were performed in serum-free MEM me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent